 |
|
|
ACTIP Bulletin 28 December 2001 |
|
|
Next ACTIP meeting:June 6-7, 2002,Amsterdam - The Netherlands
In this issue
Update European Pharmacopoeia becomes binding Industry lobbying could be better
Update European Pharmacopoeia becomes binding
The first update of the 4th edition of the European Pharmacopoeia is now available. Supplement 4.1. publishes the texts adopted at the March 2001 session of the European Pharmacopoeia Commission. It will be implemented on April 1, 2002, on which date the update becomes legally binding in all the countries that have signed the convention on the Elaboration of a European Pharmacopoeia (28 countries and the EU itself). See also:
European Parliament on proposal for FP 6
The lead Industry, External Trade, Research and Energy Committee examined the Caudron draft report on the 6th Framework Programme on 27 August (http://www.europarl.eu.int/meetdocs/committees/itre/20010827/434214en.pdf ).
Concerning the structure of the programme, the rapporteur proposes to take health out of the priority devoted to biotechnology and to regroup it with food safety and health risks in order to ensure that classic research is supported in areas such as AIDS and other scourges (this priority would be entitled "Health and safety"). Therefore the genomics and biotechnology section could also include research into health, food, agriculture etc. Ethical and social implications of R&D projects should be taken into account. In the health sector special attention is devoted to cancer, childhood diseases, cardiovascular diseases, neuro-degenerative diseases, rare diseases, resistance to medicines (including prescription patterns) and combating the three major poverty related diseases (AIDS, malaria and TB).
In the meantime the Environment Committee adopted its opinion on the 6th Framework Programme. Amendments adopted include: Creation of a new priority area devoted to health (Life Sciences for medicine and public health) in order not to confine research in the health area to biotechnology but also enable traditional research. Actions envisaged include:
Fundamental ethical principles: an amendment by Peter Liese calls for fundamental ethical principles to be respected when implementing the programme, such as human dignity, data protection, rights of animals and the environment. Where the cases arise, researchers must obtain the approval of the appropriate ethics committee before embarking on R&D project. If proposals relate to sensitive subjects, systematic ethical review will be carried out. Other amendments call for non financing through the programme of projects involving use of human embryo and use of animals whenever such experiments are avoidable, human cloning or projects resulting in alteration to the human germ line. The biotech key area should comprise projects on animal and plant model species for post-genomic research to contribute to better understanding of the biology of the human genome, and cytotherapy including adult stem cell therapy.
Source: EFPIA Newsletter September 2001
Industry lobbying could be better
A recent report on effective lobbying of the European Parliament shows that although two thirds of the MEPs rated lobbying by industry as effective, there is still lots of room for improvement. The survey of 75 Members of the European Parliament was conducted by Burson-Marsteller/BKSH and Wirthlin Europe between September-October 2001. MEPs were asked how they felt about the lobbying efforts of industry.
The survey showed some interesting results:
Source: Burson-Marsteller: "A Guide to effective lobbying of the European Parliament" (Autumn 2001)
News from the Commission
EURO 880 million for forward looking, more flexible research
On October 17 last, the European Commission adopted a proposal by Commissioner Busquin to allocate 440 million from the future EU research budget to one of the key innovative elements of the key action: "anticipating the EUs scientific and technological needs". This will cover two areas:
At a later stage another 440 million will be allocated as needs develop and new subjects emerge.
EU supports and co-ordinates stem cell research
On 13 and 14 September, the European Commissionís Research DG gathered the co-ordinators of the 15 transnational R&D projects on stem cell therapy it is currently financing with a total EU contribution of EUR 27.4 million. The meeting made clear that the over one hundred participating laboratories work on stem cells taken only from adults, from umbilical cord blood or from aborted foetuses. The projects address the scientific as well as the ethical, legal and social aspects of stem cell therapy.
EU Commissioner for research, Philippe Busquin, said: "Stem cell research is among the proposed research priorities under the next Framework Programme for research (2002 - 2006). Stem cell-based therapies hold great potential for curing diseases and injuries. I believe we can gain a lot from a stronger exchange of information and co-ordination of stem cell research across Europe. But I want to make clear that European research programmes do not, and will not, fund research on embryonic stem cells that involves the creation of an embryo for research purposes."
The so-called therapeutic cloning is excluded from EU R&D programmes in line with the recent opinion of the European Group of Ethics which said that this technology is still too immature and presents possible risks, despite its great potential.
The research project co-ordinators, together with the legal, ethics and industry experts who joined the meeting, concluded that we need to know much more about stem cells before we can predict with confidence the future outcome of this kind of novel therapy. Participants stressed that all possible sources of stem cells (adults, aborted foetuses, umbilical cord blood, early embryos) should be explored. Precluding exploration of many of these tracks would be a shortsighted decision. Europe needs a common policy and criteria for quality and safety assessment and evaluation of the efficiency of clinical trials. There is still much to do in Europe to reach an optimal level in terms of exchange of information, transparency, integration and co-operation - key objectives in the next Framework Programme
For additional information please contact:
Line Matthiessen, Quality of Life Programme, Research DG, Tel.: +32.2.295 28 53, Fax : +32 2 299 18 60 E-mail : line-gertrud.matthiessen-guyader@cec.eu.int
A full listing of all projects mentioned below, including names and contact details of coordinators, can be requested from the ACTIP Secretariat.
EU funded stem cell research under the QoL programme
In total 15 projects involving 117 laboratories with a total EC contribution of EUR 27.399.000 are currently being funded. The main topics are being addressed:
Full details of the workshop (i.e. reviews of national legislation, project abstracts etc) are available upon request from the ACTIP secretariat.
Deadlines for calls for proposals
CRAFT The two 2002 cut-off dates for submitting CRAFT project proposals have been merged into one. The last cut-off date for submitted CRAFT projects in FP 5 most likely is the 28th of February, 2002. For the Quality of Life Programme, 18 million EURO have been earmarked for this deadline. Please follow announcements in the official journal at HYPERLINK http://www.cordis.lu/sme www.cordis.lu/sme
EC contact: HYPERLINK mailto:Waldemar.kutt@cec.eu.int Waldemar.kutt@cec.eu.int
RTD projects in Key Actions
The following calls are still open and have the following deadlines:
KA 1, Food, nutrition and health: January 31, 2002
KA 4, Environment and health: January 31, 2002
KA 6, Ageing population: January 31, 2002
RDT activities of a generic nature, areas 12 and 13: January 31, 2002
Training Fellowships: April 10, 2002
Accompanying measures: February 8, 2002
Support for research infrastructures: Feb 8, 2002
Raising public awareness of science and technology: April 15, 2002 (call scheduled for 15/01/02)
SME measures (cooperative research): April 17, 2002
Marie Curie Fellowships
So far, 102 projects for Marie Curie Individual Fellowships have been selected. Equally, out of 100 proposals to host trainees from industries and PhD host institutions under the Marie Curie Host fellowships, 57 have been selected. Vacancies are listed at: http://improving-mcf.sti.jrc.it/project/
EC contact: Margherita.Mongini-Mantegazza@cec.eu.int
Stem cell news
Hybrid embryos in China
A report in the journal Nature says that scientists in China have inserted human DNA into rabbit eggs that have been stripped of their own chromosomes. The team, from the Sun Yat-Sen University of Medical Sciences in Guangzhou, hopes to use the resulting 'hybrid embryos' in embryo stem (ES) cell research. Using rabbit eggs might overcome egg shortages for experiments into ES cell research and therapeutic cloning. Chen Xigu, leader of the team, said that they had put nuclei from the skin cells of a seven-year old boy into the stripped rabbit eggs. About 100 of the embryos created developed to the morula stage, about three days of development. However, the blastocyst stage - when ES cells can be isolated from embryos - was not reached.
Sources: Nature 27/9/2001 'China plans 'hybrid' embryonic stem cells' http://www.nature.com/nature/news/010927.html#3
US experts want more stem cells
The stem cell debate in America continues. The US National Academy of Sciences, an advisory body to the government, has produced a report stating that the 64 embryonic stem cell lines identified by Bush as eligible for federally funded research will not be enough to progress with the science. It says that new stem cell lines will be needed in order to facilitate research, even though President Bush has said that research will only be allowed to take place on those already in existence. The panel also voiced its support for therapeutic cloning. In addition, the academy also advised that the US National Institutes of Health (NIH) set up an advisory group to continually monitor and oversee research on human embryonic stem cells because of the ethical problems that arise. It also calls for more federal funding for stem cell research. Meanwhile, the Michael J Fox Foundation for Parkinson's Research (MJFF) has pledged $2.2 million in funding for a research program that aims to produce a stem cell line with benefit to Parkinson's disease patients. Proposals for the award will be based on merit, rather than the source of the cells to be used, a MJFF spokesperson said.
Sources: - Yahoo Daily News 10/9/2001 'Group offers $2.2 million for stem cell research' http://dailynews.yahoo.com/htx/nm/20010910/hl/stemcell_2.html - The Washington Post 11/9/2001 'Broader stem cell research backed' - The Washington Post: http://www.washingtonpost.com/ac2/wp-dyn/A7126-2001Sep11
and a bill allowing limited federal funding.
A bill approved last week recently by a
subcommittee of the US Senate would allow limited federally financed
stem cell research, and give President Bush discretion
over how to control this. The proposal would allow Bush to follow
through on his proposal to restrict the research
to the 64 stem cell lines that he said
already exist.
Source: - Yahoo Daily News 10/10/2001 'Senate panel OKs stem cell bill' - Yahoo Daily News: http://dailynews.yahoo.com/htx/ap/20011010/pl/senate_stem_cells_2.html
Spain no, Netherlands yes to embryonic stem cell research
The Spanish parliament has voted against a proposal to allow the use of embryonic stem (ES) cells from embryos created originally for in vitro fertilisation (IVF). A government spokesman said that the proposal was rejected because an 'Advisory Committee on Ethics of Scientific and Technological Research' must be set up. He also said that future projects were not at risk because the government were 'aware of 40,000 spare embryos' in existence in Spain. Meanwhile, the Netherlands has approved a new law allowing embryo research, including embryonic stem cell research, but not the use of therapeutic cloning. Dutch MPs have voted, after a year of debate, not to amend the Netherlands embryo bill to allow the possibility of creating embryos specifically for research. Scientists will be allowed to use embryos 'left over' from in vitro fertilisation techniques, but only where there is informed consent from a donor enabling them to do so and approval has been given by a central committee. Human cloning, embryonic sex selection and the combining of human and animal embryos remain prohibited.
Sources: - The Lancet 20/10/2001 'Spain closes the door on embryonic stem cell research' - The British Medical Journal 19/10/2001 'Netherlands votes in favour of therapeutic cloning' http://www.bmj.com/cgi/content/full/323/7318/884/a
Australian panel divided on stem cell regulation
After a two-year enquiry, an Australian parliamentary panel has made recommendations on how the country should regulate stem cell research. Six of the ten panel members voted for fairly permissive legislation, which would allow scientists to derive stem cells from embryos donated by IVF patients, provided the necessary consent was obtained. Work on these cells would, it was recommended, be strictly regulated. The rest of the panel opposed the use of these embryos, saying that research could take place on existing stem cell lines, six of which are known to be in Australia. The panel did not rule out therapeutic cloning, but it has suggested that a three-year moratorium on the practice be imposed, after which time it will be reappraised.
Source: - BBC News Online 2/9/2001 'Australia edges forward on stem cells' http://news.bbc.co.uk/hi/english/sci/tech/newsid_1555000/1555914.stm
Regulation in India and Israel
The Indian Council of Medical Research (ICMR) has said that India is to bring in stringent new guidelines to govern stem cell research. Currently, IVF and assisted reproduction are unregulated in India, and there is no ban on the use of 14-day old embryos for research. Ten of the named stem cell lines eligible for federally funded research in the US are held in India. The new guidelines will prevent international commercial trade in human embryos and regulate the transfer of ES cell lines for foreign use. IVF clinics will be given an accreditation system, as they are seen as the largest source of embryos. A central ethics committee will be set up to monitor and regulate progress and research. Finally, Science reports that Israel's national bioethics committee has approved both the derivation of ES cells and research into therapeutic cloning.
Source: Yahoo Daily News 29/9/2001 'India framing strict laws for stem cell research': http://in.news.yahoo.com/010929/43/15pfr.html
Business News
UK, genetics and insurance
On October 23, insurance companies in the UK have promised to not use genetic tests for a period of 5 years. 65 British insurance companies admitted that they have used genetic information during the past year. This information was often used to increase an insurance premium or to refuse one. The majority of tests related to investigations into Huntingdon's disease or early susceptibility for Alzheimer's disease. In most European countries genetic information is not used by insurance companies. http://www.guardian.co.uk/Print/0,3858,4283734,00.html
Quality and safety standards for human blood and blood components
During the September plenary session, members of the European Parliament adopted a report on quality and safety standards for human blood and blood components. They adopted a number of technical amendments on collection, storage and testing of blood (e.g. haemovigilance and traceability). They insisted on the non-commercial character of blood donations and recommended that blood should be collected from voluntary and non-remunerated donors only in order to reduce risk for donors and patients. MEPs also recommend that more attention be paid to umbilical cord blood and adultíís blood donation in the context of stem cells research. The final EP resolution is available on the following website: http://www3.europarl.eu.int/omk/omnsapir.so/pv2?PRG=CALEND&APP=PV2&LANGUE=EN&TPV=PROV&FILE=010906
Parliament reviews pharmaceutical legislation
On 13 September 2001, the Environment, Public Health and Consumer Policy Committee of the European Parliament held an exchange of views with EMEA Director, Mr Lˆnngren, about the present and the future of EMEA and pharmaceutical legislation. Mr Lˆnngren said that the EMEA existence had been until now a success story; a good evaluation of its work is provided in the Commission report and its competence strengthened in the draft review of pharmaceutical legislation. Speaking about the future, he mentioned the increasing number of applications and new tasks required from the Agency due to the Orphan Drugs Regulation, the Clinical Trials Directive, as well as the accession of new Member States. All these aspects will require a discussion on how the Agency should be financed in the future. Issues raised by MEPs during the debates: Pharmacovigilance and Clinical studies strengthening a centralised coordination in the pharmacovigilance process and continuous training of doctors to this effect. training of doctors should not be only in the hands of industry reps industry to devote a small percentage of its benefits to a fund to carry out pharmacovigilance tasks. possible sanctions for companies and member states which fail to comply with pharmacovigilance requirements long-term effects studies to be carried out before a marketing authorisation is granted (authorisations are granted too quickly for patent reasons) clinical studies to be carried out by independent bodies such as EMEA
Source: EFPIA Newsletter September 2001
EMEA sees rise in adverse reactions
EMEA is calling for extra resources to investigate a steep rise in reports of adverse reactions to drugs it has approved. The reactions range from hot flushes to deaths. The EMEA is expecting to receive 35,000 of such reports from doctors this year, which is up from around 26,000 in 2000 and 16,000 in 1999. The reports are a reaction on more and more drugs getting onto the market. EMEA says it needs more resources to meet increasing demands for in-depth reviews and assessments. Besides gathering reports, EMEA is already setting up an online database that will track the problems as soon as they are known. Already, the EMEA staff is preparing itself for a heavy 35% increase of workload following a pharmaceutical review tabled by the Commission, which would require firms to submit all new products to EMEA for approval instead of being allowed to choose between its centralised procedure and approval by national authorities.
Source: European Voice October 31, 2001-12-03
Short Research News
Yeast sensors for drug discovery
The November issue of Nature Biotechnology describes a generic sensor that allows detection of drug binding to a target by a simple growth assay in Saccharomyces cerevisiae. Yeast-based screens could provide a simple means to identify compounds that bind to a protein target or to perform structure-function analysis. Source: Nature Biotechnology Vol 19, p 1042-1046
Quartz crystals as viral detectors
Quartz crystals can be used as detectors for viruses. The crystals vibrate in response to electric fields, and the frequency of this vibartion increases in proportion to the mass of a foreign object attached to its surface. By increasing the frequency beyond a certain point, the virus breaks loose, and this rupture evnet can be detected by the quartz disk doubling as a miniature microphone. The resolution is detecting a single viral particle in a microliter of sample. Source: Nature Biotechnology Vol 19, pp. 833-837
Science and art
The newest portrait at the National Portrait Gallery in London is a DNA portrait of geneticist Sir John Sulston. The portrait is by Marc Quinn, the young artist who became famous for his sculpture 'Self', which was made from his own deep-frozen blood. Sulston donated his sperm for the work, from which a sample of DNA was taken. This was put in agar jelly and bacterial cultures were grown to make the image which is framed in stainless steel to represent a sterile, scientific environment.
Source: - BBC News Online 19/9/2001 'Gallery puts DNA in the frame' http://news.bbc.co.uk/hi/english/entertainment/arts/newsid_1550000/1550864.s tm - The British Medical Journal: http://www.bmj.com/cgi/content/full/323/7314/652/e
Fertility preserved by ovary transplants
Ovarian transplants may be successful in preserving the fertility of women who have recovered from cancer. Ovarian tissue was collected from 18 women with lymphoma, and grafted into a strain of mice that did not have working immune systems. Tissue from the lymph nodes of the women was grafted into another group of the mice as a control. It was found that the mice that received the ovarian tissue did not develop cancer, while all those that received the lymph tissue did. Another research project has shown that ovarian tissue transplanted into the arm of women before cancer treatment may prevent premature menopause in younger women and perhaps also preserve fertility. Hormone production continued.
Sources: - BBC News Online 27/9/2001 'Ovary transplant safety fears eased' http://news.bbc.co.uk/hi/english/health/newsid_1565000/1565285.stm Reuters Health 25/9/2001 'Ovarian tissue transplant may preserve fertility' http://www.reutershealth.com/archive/2001/09/25/eline/links/20010925elin014 .html
300 million pounds for functional genomics:
The Sanger Centre, near Cambridge, has recently announced a five-year plan to try to identify as many genes as possible, try to determine their functions, and establish which regions control their expression. The Wellcome Trust, the world's biggest biomedical charity, will sponsor the work, spending £300 million on the new research. The Centre is changing its name to become the Wellcome Trust Sanger Institute.
Source: - The Financial Times 19/10/2001 'Post-genomic studies funded' - The Financial Times: http://globalarchive.ft.com/globalarchive/article.html?id=011019000977
Scientists sequence black death
The genetic sequence of the bacteria that causes Black Death, otherwise known as the plague, has been decoded. The discovery may lead to the production of a vaccine or treatments for the disease, which still affects people around the world today and is viewed as a potential weapon for bio-terrorists. It was found that the plague bacterium is a recent descendant of a benign stomach-dwelling bug, which is thought to have evolved over only a few hundred years, a relatively short time. In doing so, it learnt to move from fleas and mammals to humans, where it adapted to live in the blood, rather than the gut.
Source: - Nature Science Update 4/10/2001 'Black Death's DNA' http://www.nature.com/nsu/011004/011004-12.html
Metabolomics of Bacillus
Dutch TNO Nutrition and Food Research, together with a global biotechnology company, will establish the full metabolome (the complete set of metabolites present in a cell) of Bacillus subtilis. The metabolome is estimated to consist of 1,000 different metabolites.
Source: TNO press release, August 18, 2001
Dolly technique used to clone endangered sheep
Scientists have managed to successfully clone a mouflon lamb, the first time that an attempt to clone an endangered species has been successful. The European Mouflon is a rare breed of sheep found on the mediterranean islands of Sardinia, Corsica and Cyprus. The lamb was cloned using the same technique used to produce Dolly the sheep. The genetic material of a ewe found dead in a Sicilian wildlife rescue centre was used. DNA was taken from the carcass and placed in empty egg cells 'donated' by domestic sheep. The resulting embryos were carried to term by other domestic sheep acting as surrogates. Genetic tests have revealed that the lamb, now six months old, is a true clone.
Source: BBC News Online 1/10/2001 'Endangered sheep cloned' http://news.bbc.co.uk/hi/english/sci/tech/newsid_1573000/1573309.stm
Neuron cultured on microchip
Recently it has become possible to culture neuronal cells of Lymnia stagnales on the silicon coating of a microchip. The chip carries a impulse-generating and an impuls-recording part. To prevent the neuronal cells moving during their growth, the researchers equipped the chip with a microscopic fence. The chip was used to measure the synaptic activity between various neurons of the snail. The chip can be used in further research on neuroprosthetics and artificial neurons.
Source: Nature Biotechnology 19, 927; Nature Biotechnology 19, 121-124;
On the web
Publications
Issue of Euroabstracts on The Genome and Human Health. Published by EC Innovation/SME programme. Vol 39/4/2001. August 2001. See also: http://www.cordis.lu/euroabstracts/en/ausut
SME website
On CORDIS, a special website exists which combines all information on specific measures for SMEs. For help you may also contact the SME National Contact Points, which can advise you or help you in searching for a partner. http://www.cordis.lu/sme/src/sme-ncps.htm
EUR-Lex: EU legal texts on web
The EU Institutions have created a single entry point to EU legal texts, called EUR-Lex. One may find the Official Journal, the Treaties, legislation in preparation, case law, parliamentary questions and documents of public interest. Documents are available in html, pdf and tiff. Some are subject to payment. See:
European research news centre
The Research DGs homepage now includes a new service - European Research - News Centre. It provides access by major scientific topics to hundreds of articles and project profiles, as well as other information published by the European Commission on scientific, technological and political development in the European Research Area. Visit: http://europa.eu.int/comm/research/news-centre/index_en.html
AlphaGalileo &endash; research-media interface
AlphaGalileo is a mediator of scientific information. It now has some 1,100 contributors in Europe, including universities, research networks, companies and specialist publishers. AG is mainly intended for journalists and media professionals. It also has a searchable database of all press releases received. A recently launched service allows journalists to directly contact European experts best qualified to answer their questions in particular fields. Visit:
Public discussion board
A new public discussion board has opened on the web. It deals with discussions on gene synthesis, molecular biology problems, and life science issues in general. The board is expected to foster the discussions around the emerging applications of synthetic genes in an open and easy-to-access environment.
Jobs
An online Job Resource Centre is accessible by: http://www.iets.org and click on Job Resource Centre Link http://www.entelechon.com/genetalk/index.php3
Online marketplace
Online market places for the pharmaceutical and chemical manufacturing and process industries can be found on BioPharmaWeb and EuroChemWeb. Visit:
http://pull.xmr3.com/p/114-47C9/10691005/http-www.BioPharmaWeb.com.html
http://pull.xmr3.com/p/114-47C9/10691011/http-www.EuroChemWeb.com.html
Nobel Prize
The Nobel Prize now exists exactly 100 years (established in 1901). There are several interesting websites:
Nobel museum: http://www.nobels-bjorkborn.t.se/index-eng.html Exhibition on Nobel Prize: http://www.bigidea.org/uk Nobel Prize website: http://www.nobel.se
AGENDA
A number of interesting conferences and workshops is coming up. Of all the events mentioned here, the detailed programmes and registration/application forms are available from the ACTIP secretariat. .
Conference " Stem Cells: Therapies for the Future ? " in Brussels, on 18-19 December 2001
This " Life Sciences Discussion Platform " aims at fostering a pluralistic and reciprocally informative debate between science and society on novel concepts of therapies - based on the use of stem cells - with promising potentials for the medicine of the future and with important societal and ethical implications.
Expected participants Scientists, experts in the ethical implications of biotechnology, specialists in human sciences and law, associations of patients, interest groups, students and teachers, educators and media, the medical profession and various representatives of public authorities
Date: December 18 and 19, 2001 Place: Charlemagne Building, Brussels, Belgium Central contact: Elisabetta.Balzi@cec.eu.int Web: http://europa.eu.int/comm/research/quality-of-life/stemcells.html
Lab-on-a-chip and Microarrays for post-genome applications January 14-16, 2002, Zurich Switzerland
Integrated BioInformatics ñ high throughput interpretation of pathway and biology January 16-18, 2001, Zurich, Switzerland Organization: Cambridge Health Tech Institute: http://www.healthtech.com
O'Reilly Bioinformatics Technology Conference January 28-31, 2002, Tucson, Arizona Organization: http://conferences.oreilly.com/biocon
The Genome and beyond &endash; genomics and structural biology for medicine February 2-6, 2002, Miami Beach, Florida Organization: Nature Biotechnology, http://www.med.miami.edu/mnbws
GenomExpo February 6-8, 2002, Paris, France Organization: http://www.edd-salons.com/
BioSquare 2002 &endash; the Partnering Event February 27-March 1, 2001, Zurich, Switzerland Organization: ebdgroup. http://www.ebdgroup.com/biosquare
Days of Molecular Medicine (rescheduled) March 13-16, 2002, San Diego, California Organization: http://imm.ucsd.edu
The New York Biotechnology Associations 11th annual meeting March 18-19, 2002, New York, NY USA Organization: minfo@nyba.org
Pharmaceutical products and viral safety March 14-15, 2002, Paris France Organization: Institut Pasteur Euroconferences. Fax: + 33 1 40 61 34 05. www.pasteur.fr/applications/euroconf
Next ACTIP meeting: June 6-7, 2002, Amsterdam Organization: ACTIP Secretariat. Email: ACTIP@ACTIP.org
BIO 2002 June 9-12, 2002, Metro Toronto Convention Centre Organization: BIO NY
18th ESACT meeting Animal Cell Technology meets Genomics May 11-15, 2003, Granada, Spain Organization: ESACT, http://www.esact.org + 34 932 388 777
ACTIP Bulletin nr. 28, December 2001
For more information:
ACTIP Secretariat. P.O. Box 9143, 3007 AC Rotterdam, The Netherlands Tel: + 31 10 482 83 06; Web: http://www.actip.org
|